Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Gynecologic 1Genitourinary 1Gastrointestinal 1Dermatologic 1

Conditions

Squamous Cell Carcinoma of Head and Neck 2Melanoma 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, Follicular 2Carcinoma, Renal Cell 2Carcinoma, Non-Small-Cell Lung 2Uveal Melanoma 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Stomach Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma 1Lung Neoplasms 1Liver Neoplasms 1Kidney Neoplasms 1Head and Neck Neoplasms 1Colorectal Neoplasms 1Carcinoma, Hepatocellular 1Breast Neoplasms 1Advanced/Metastatic Solid Tumors 1Advanced Solid Tumors 1

Interventions

Radiotherapy 39pembrolizumab 37Carboplatin 37Cisplatin 34Paclitaxel 26Pemetrexed 24Docetaxel 18Nivolumab 17Magnetic Resonance Spectroscopy 17Gemcitabine 17Bevacizumab 17Specimen Handling 16Cyclophosphamide 15osimertinib 14Radiation 13Irinotecan 13Etoposide 13Erlotinib Hydrochloride 12durvalumab 11Topotecan 10Cetuximab 10Radiosurgery 9Immunoglobulin G 8Fluorouracil 8Everolimus 8Disulfides 8Celecoxib 8fludarabine 7Taxes 7Ipilimumab 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Lung Neoplasms × utomilumab × Clear all
NCT02315066 2022-04-21

Study Of OX40 Agonist PF-04518600 Alone And In Combination With 4-1BB Agonist PF-05082566

Pfizer

Phase 1 Completed
174 enrolled 68 charts
DermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Uveal Melanoma, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Kidney Neoplasms, Liver Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Neoplasms, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡